Medical Condition News

RSS

Three-drug combination therapy appears to be effective for newly diagnosed MM patients

A three-drug combination treatment for the blood cancer multiple myeloma compares favorably to the best established therapy for newly diagnosed patients, according to a multi-center study led by Andrzej Jakubowiak, MD, PhD, professor of medicine and director of the multiple myeloma program at the University of Chicago Medical Center.

13 Dec 2011

Infants with low salivary cortisol levels develop fewer allergies

A new study from the Swedish medical university Karolinska Institutet shows that infants with low concentrations of the stress-related hormone cortisol in their saliva develop fewer allergies than other infants. Hopefully this new knowledge will be useful in future allergy prevention.

13 Dec 2011

FDA approves Lannett's ANDA for Triamterene with Hydrochlorothiazide Capsules

Lannett Company, Inc. today announced it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Triamterene with Hydrochlorothiazide 37.5/25mg Capsules.

13 Dec 2011

Geron commences GRN1005 Phase 2 trial in breast cancer

Geron Corporation today announced the initiation of GRABM-B (GRN1005 Against Brain Metastases - Breast cancer), a Phase 2 clinical trial to evaluate GRN1005 in patients with brain metastases arising from breast cancer.

13 Dec 2011

ADHD drugs not bad for the heart: Study

Drugs widely prescribed for attention disorders like Ritalin, Adderall and other drugs, did not increase the risk of serious heart problems in a major study published Monday. This could assure parents of children on these medications on heart-related safety of the medicines.

12 Dec 2011

Alternative cures for cancer lure people and may cause more harm than good: Study

According to doctors thousands of cancer patients are turning to alternative treatments that could harm them and ultimately claim their lives. There have been cases of alternative practitioners who have tricked vulnerable patients into fraudulent cancer therapies. This fails to deter most people shows a new study.

12 Dec 2011

Alzheimer’s disease vaccine developed by Australian scientists

Scientists from the University of Sydney on Saturday have announced that they have developed a vaccine to help halt the progression of Alzheimer's disease of humans. The progress of neurodegenerative condition affects more than 35 million people worldwide.

12 Dec 2011

Sound sleep despite technology overload: Study

Researchers at the University of Sydney have found there has been no significant change over almost 20 years in the average amount of sleep that Australians are getting. There have been concerns that an average Australian might be losing out on sleep due to the technology overload from computers and mobile phones.

12 Dec 2011

Bone drug effective in improving breast cancer survival

In a chance finding a bone drug was found to be effective in breast cancer. While doctors were prescribing young women a medicine to keep their bones strong during breast cancer treatment they noted that after seven years it did more than that - the bone drug improved survival, as much as most chemotherapy could do.

12 Dec 2011

Gene therapy for bleeding disorder Hemophilia B

In a landmark study, researchers used gene therapy to successfully treat six patients with severe hemophilia, a blood-clotting disorder. Despite the early nature of the study, it is promising. A single infusion using the new treatment worked in some patients for more than a year, boosting their clotting ability significantly.

12 Dec 2011

IRIDEX announces data from MicroPulse laser therapy study on DME

IRIDEX Corporation today announced that data from a clinical study compiled over 10 years demonstrates the safety and efficacy of MicroPulse laser therapy for treating diabetic macular edema (DME) without the retina tissue damage associated with conventional laser therapy.

12 Dec 2011

Second annual clinical meeting of Cell Society to be held in San Diego

Although demand and interest in adult stem cell therapies are increasing, it has been challenging for physicians, patients and policy-makers to retrieve the most current and accurate information available. Cell Society International is a nonprofit organization dedicated to advancing the clinical applications of adult stem cell therapies worldwide. Cell Society firmly believes that cell therapies offer improved medical treatment for many complicated and hard to treat diseases/injuries.

12 Dec 2011

InVivo co-founder receives 2011 The Economist annual Innovation Award in Bioscience

InVivo Therapeutics Holdings Corp., a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today congratulates Robert S. Langer, Sc.D., InVivo co-founder and member of the Company's Scientific Advisory Board, for his selection as the recipient of the 2011 The Economist annual Innovation Award in Bioscience.

12 Dec 2011

WTC disaster results in increased risk of physical and mental health conditions after 9/11

The World Trade Center disaster exposed nearly half a million people to hazardous chemicals, environmental toxins, and traumatic events. According to research published in the December 2011 issue of Elsevier-published journal Preventive Medicine, this has resulted in increased risk of developing physical and mental health conditions after 9/11.

12 Dec 2011

Soligenix reports results from orBec Phase 2 trial on acute GVHD

Soligenix, Inc., a development stage biopharmaceutical company, announced the publication of results from its investigator-initiated Phase 2 "proof-of-concept" exploratory clinical trial of orBec for the prevention of acute Graft-versus-Host disease (GVHD) in patients undergoing myeloablative conditioning regimens with initiation of dosing prior to hematopoietic cell transplantation (HCT) and continuing through the post-transplantation period.

12 Dec 2011

Mazor Robotics to purchase Renaissance system for spine surgeries

Mazor Robotics Ltd., the leader in innovative surgical robots and complementary products for spine surgery, signed an agreement for the purchase of a Renaissance system with Richard R. M. Francis, MD, of Spine Associates of Houston and the Houston Orthopedic and Spine Hospital, formerly known as Foundation Surgical Hospital, in Bellaire, Texas.

12 Dec 2011

Reata, Abbott partner to develop and commercialize AIMs for chronic diseases

Abbott and Reata Pharmaceuticals today announced that they have entered into a worldwide collaboration to jointly develop and commercialize Reata's portfolio of second-generation oral antioxidant inflammation modulators.

12 Dec 2011

Technique expands scarce resources used for cord blood transplant procedure

A new method to boost the number of immune cells in umbilical cord blood prior to cord blood transplants for cancer patients appears to lead to a quicker rebuilding of a new immune system in the patient's body than with a conventional cord blood transplant procedure, according to new research from the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 53rd American Society of Hematology Annual Meeting.

12 Dec 2011

Treatment with leukemia patients' own cells may prevent infections after chemotherapy

A new treatment using leukemia patients' own infection-fighting cells appears to protect them from infections and cancer recurrence following treatment with fludarabine-based chemotherapy, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

12 Dec 2011

Celgene announces interim results of REVLIMID study on CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced interim results of CLL-009, a study evaluating three starting doses of REVLIMID (lenalidomide), followed by step-wise dose escalation as tolerated in patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

12 Dec 2011